Matakina and Viztek Partner to Integrate Breast Density Assessment, Creating First Complete RIS/PACS Breast Imaging Software Suite

“Our integration with VolparaDensity extends our capabilities and enables us to provide a more complete women’s healthcare software suite,” said Steve Deaton, vice president at Viztek. “With viewing, tracking, and now breast density software integration for RIS and PACS, Viztek has the first complete package for mammography and is enabling increased efficiency with the potential for better results.”

Cleared by the FDA, HealthCanada, the TGA and CE-marked in Europe, VolparaDensity is in use at sites across the globe helping radiologists assess breast density more objectively and enabling them to better consider who might benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity generates an objective, automatic measurement of volumetric breast density and an FDA-cleared BI-RADS breast density category.

“Creating an objective, reproducible value within the RIS/PACS workflow is critical, not only for efficiency in practice, but for meeting the demands of new breast density legislation,” explains David Mezzoprete, vice president of sales at Matakina. “Our partnership with Viztek establishes a new model for diagnosis and exam follow-up in this new era of regulated density reporting, and we are proud to play a role in enhancing patient care.”  

Studies have shown traditional FFDM is only 48% effective in women with dense breasts, who also happen to be more susceptible to cancer. The estimated 40% of women in the U.S. who have dense breasts may benefit from adjunctive imaging modalities, such as ultrasound, MRI or molecular breast imaging, which can provide a clearer view of potential “hidden” cancers.

With the Viztek and Matakina partnership, smooth RIS/PACS integration of density data provides a significant increase in efficiency and also will aid in objectivity. The VolparaDensity output is done via the secondary capture to the Viztek Opal-PACS and structured report to the Opal-wRIS. The RIS will then take the data and put it automatically into the patient “lay letter” for mammography reporting functionality and streamlined workflow for the facility.

“We’re helping doctors make good decisions, and we’re the first in the industry to include density determination as part of a comprehensive plan,” says Deaton. “It’s the future of breast care and Viztek is leading the way.”